Navigation Links
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
Date:5/14/2008

elcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding the further development and potential safety, efficacy, regulatory status, commercial potential and other characteristics of Kosan's product candidates; the continuation of current clinical trials; the initiation of additional clinical trials and the timing thereof and the use of Kosan's financial resources. Words such as "will," "expect," "believe," "may," "intend," "plan," "potential" and similar expressions are intended to identify forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Kosan's current expectations. Forward-looking statements involve risks and uncertainties. Kosan's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the uncertain progress and r
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
9. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Oct. 31, 2014  Zebra Imaging, Inc., the ... announced today a strategic partnership with the Zygote ... 3D anatomy and biomedical models for animation and ... education markets.  Zygote maintains the world,s most comprehensive ... and has pioneered development of high-end solid 3D ...
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)...  Zacks.com announces the list of stocks featured in the Analyst ... news and events impacting stocks and the financial markets. Stocks recently ... - Free Report ), Celgene (Nasdaq: CELG - ... Free Report ), Market Vectors Biotech ETF (AMEX: BBH ... XBI - Free Report ). Today, ...
Breaking Medicine Technology:Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... - ViziLite Plus with TBlue630 -, PHOENIX, Sept. ... with Tblue630(TM) screening system for early detection of,abnormalities which ... identify,pre-cancerous lesions in a Phase II study of Cetuximab ... developed by ImClone,Systems (Nasdaq: IMCL ) and distributed ...
... Secondary Endpoints, San Carlos, Calif., Sept. 4 ... company focused on developing novel,pain management therapies, today ... of NGX-4010, the Company,s dermal patch containing,the TRPV1 ... postherpetic,neuralgia (PHN). The study, a multi-center, double-blind, controlled ...
Cached Medicine Technology:Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 2NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 3NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 4NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 5NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 6NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia 7
(Date:10/31/2014)... CA (PRWEB) October 31, 2014 ... also has amazing health effects for practitioners. ... by a Doctor of Science and Movement specializing ... his dedication to pelvic floor reeducation that traditional ... urinary incontinence, Diastasis Recti, Prolepses, etc. , The ...
(Date:10/31/2014)... Energy Textiles has recently added a new ... now available online, and Energy Textile is providing their ... athletic gear over compression gear. , The Boston ... signed for Under Armour to provide team gear for ... In light of this decision, Energy Textiles contemplates whether ...
(Date:10/31/2014)... treatment and cost, patients with early stage breast ... (APBI) with proton therapy versus whole breast irradiation ... of Texas MD Anderson Proton Therapy Center. ... on typical patient characteristics, researchers used Medicare reimbursement ... types of partial and whole breast irradiation therapies ...
(Date:10/31/2014)... Gold Medal Wine Club is making it ... for the wine novice and enthusiasts on their lists with ... , which Early Bird shoppers receive discounts as high as ... , Gift Givers must place their orders before November ... Gold Medal Wine Club adds more value to its Wine ...
(Date:10/31/2014)... a drug combination that can trigger the self-destruct process ... new treatments, according to research that will be presented ... in Liverpool next week*. , When healthy cells are ... culminating in self destruction. But cancer cells swerve away ... that cells grow out of control – causing tumours ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... $18 million research program headed by Washington University ... and diagnostic tools for heart and lung diseases ... Heart, Lung, and Blood Institute, will fund five ... collaborating,institutions: Texas A&M University, University of Texas Southwestern ...
... The Alzheimer,s Association has awarded a three-year, $200,000 ... The University of Texas Health Science Center at Houston ... Alzheimer,s disease. "The main goal of this project ... such as a blood test that can tell people ...
... A team of researchers led by a Michigan State University ... for breast cancer in young women, focusing on growth, diet, ... The five-year study, funded by the National Institutes ... of Human Medicine,s Department of Epidemiology, will include the largest ...
... traumatic event a car accident, a physical or ... many as 1 in 5 children will develop Posttraumatic ... helps improve communication between child and caregiver, such as ... skills, was able to prevent chronic and sub-clinical PTSD ...
... Minn. -- In the largest, most modern, single-institution ... a long-term data registry for survival rates of ... for localized prostate cancer. The findings are being ... American Urological Association,s 84th Annual Meeting in Chicago. ...
... HealthDay Reporter , TUESDAY, Sept. 28 (HealthDay News) -- ... proteins may indicate the presence of prostate cancer more accurately ... The test, which has thus far only been assessed ... fewer false-positive results than the prostate specific antigen (PSA) test, ...
Cached Medicine News:Health News:WUSTL awarded $18 million to treat heart, lungs with nanotechnology 2Health News:WUSTL awarded $18 million to treat heart, lungs with nanotechnology 3Health News:MSU researcher awarded $14 million to identify breast cancer risk factors 2Health News:After traumatic event, early intervention reduces odds of PTSD in children by 73 percent 2Health News:Surgery offers long-term survival for early stage prostate cancer patients 2Health News:Experimental Test May Spot Prostate Cancer Earlier, More Accurately 2Health News:Experimental Test May Spot Prostate Cancer Earlier, More Accurately 3
The Hypervisor VI is a solution for telemetry, LAN and wireless LAN networking. It includes bi-directional communication with Mindray bedside patient monitors and can store waveforms and numeric info...
DS 7600 Central Station...
... DLE (Drug List Editor) Multi-Channel Infusion System ... technology. The instrument combines three independent infusion ... in an unparalleled small size. Now with ... Infusion System simplifies the delivery of complex ...
... SRS Freedom Chart Manager provides powerful workflow ... order management, integrated transcription services, and customized ... engine that eliminates the need for paper ... benefits of a paperless office now and ...
Medicine Products: